Maroteaux-Lamy syndrome exhibits deficient activity of the enzyme arylsulfatase-B in cultured skin fibroblasts. Prenatal diagnosis was successfully attempted in two pregnancies of a consanguineous Chaldean couple whose first child is affected with Maroteaux-Lamy syndrome. In both instances, deficient arylsulfatase-B activity was observed in amniotic fluid cell cultures, and the diagnosis was confirmed by 35S-sulfate studies and postmortem enzymology and electron microscopy. The prenatal diagnosis of Maroteaux-Lamy syndrome remains problematic. Residual activity of arylsulfatase-B in the affected homozygote can make interpretation difficult, and the behavior of many lysosomal enzymes varies greatly in response to tissue culture conditions and enzyme extraction processes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajmg.1320080215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of inversion with breakpoints in causing MPS VI by whole-genome sequencing: lessons learned and best practices.
Front Genet
January 2025
Genetics and Precision Medical Center, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Mucopolysaccharidosis type VI (MPSVI), an autosomal recessive lysosomal storage disorder caused by pathogenic variants in gene. Usually, whole exome sequencing (WES) can identify these variants, and if WES failed to detect causative variants, whole-genome sequencing (WGS) may be considered to investigate deep intronic variations and structural alterations in patients.
Methods: Whole-exome sequencing (WES) and whole genome sequencing (WGS) were performed in a Chinese family having a boy with suspected diagnosis of MPS with macrocephaly, coarse facial features, broad forehead, thick lips, frontal bossing, craniosynostosis, blue spots, frequent upper respiratory infections, inguinal hernia, and dysostosis multiplex.
Three-dimensional Evaluation of Gait: Kinetics, Kinematics, and Electromyographic in Patients with Mucopolysacharidosis Types IV and VI.
Rev Bras Ortop (Sao Paulo)
October 2024
Universidade Federal de Pernambuco, Recife, PE, Brasil.
This study evaluated and determined, through instrumented three-dimensional (3D) gait analysis, the kinetic, kinematic, and electromyographic profile of patients with mucopolysaccharidosis (MPS) IV and VI. This crossectional study included 11 patients treated at a rare diseases reference service and evaluated in a movement analysis laboratory. We collected clinical, physical examination, and kinetic, kinematic, and electromyographic data using a 3D movement system, from June 2020 to January 2021.
View Article and Find Full Text PDFMorphological abnormalities in the white blood cells of a baby with type VI mucopolysaccharidosis.
Ann Biol Clin (Paris)
November 2024
Laboratory of hematology, CHU Brugmann LHUB-ULB site Horta 4, Pl Van Gehuchten, 1020 Brussels Belgium.
Molecular analysis of mucopolysaccharidosis type VI in Iranian patients; the influence of founder effect and consanguinity.
Mol Biol Rep
November 2024
Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Background: Mucopolysaccharidosis type VI (MPS VI), also known as Manteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase B(ARSB). This syndrome is progressive and affects many tissues and organs, leading to inflammation and scarring. The classic clinical features of Maroteaux-Lamy syndrome are significant impairment of the osteoarticular system with dysostosis multiplex, short stature and motor dysfunction.
View Article and Find Full Text PDFEndocannabinoid receptor 2 is a potential biomarker and therapeutic target for the lysosomal storage disorders.
J Inherit Metab Dis
January 2025
Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Article Synopsis
- The study investigated the expression of the endocannabinoid receptor 2 (CB2R) in various animal models of lysosomal storage disorders (LSDs) to evaluate its potential as a biomarker and therapeutic target.
- CB2R levels were significantly increased in the plasma and tissues of specific LSD models, such as Farber disease and mucopolysaccharidosis type IIIA, while other models showed minimal or no increase.
- Treatment with CB2R agonists not only reduced CB2R and inflammatory markers like MCP-1 in LSD patient cells and mice but also improved their performance in functional tests, suggesting the need for further research on CB2R as a therapeutic target and biomarker for monitoring treatment efficacy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!